N4 Pharma PLC Result of AGM (1932V)
03 Avril 2023 - 3:11PM
UK Regulatory
TIDMN4P
RNS Number : 1932V
N4 Pharma PLC
03 April 2023
3 April 2023
N4 Pharma plc
("N4 Pharma" or the "Company")
Result of Annual General Meeting
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for cancer treatments
and vaccines, is pleased to announce that at its annual general
meeting ("AGM"), held earlier today, all resolutions were duly
passed.
Against Witheld
Resolution For For% Against % Total votes*
Ordinary Resolution
1 - To receive
the annual report
and audited
accounts for
the year ended
31 December
2022 20,267,523 99.37% 127,579 0.63% 20,395,102 19,729
----------- ------- -------- -------- ----------- --------
Ordinary Resolution
2 - To re-elect
John Chiplin
as a Director
of the Company 20,004,322 98.08% 390,780 1.92% 20,395,102 19,729
----------- ------- -------- -------- ----------- --------
Ordinary Resolution
3 - To re-elect
Luke Cairns
as a Director
of the Company 20,165,927 98.88% 229,175 1.12% 20,395,102 19,729
----------- ------- -------- -------- ----------- --------
Ordinary Resolution
4 - To re-elect
Chris Britten
as a Director
of the Company 20,004,322 98.87% 229,175 1.13% 20,233,497 181,334
----------- ------- -------- -------- ----------- --------
Ordinary Resolution
5 - To re-appoint
Saffery Champness
LLP as the Company
s auditor and
to authorise
the Directors
to determine
their remuneration 20,037,518 98.25% 356,384 1.75% 20,393,902 20,929
----------- ------- -------- -------- ----------- --------
Ordinary Resolution
6 - To authorise
the Directors
to allot shares 19,996,465 98.36% 333,237 1.64% 20,329,702 85,129
----------- ------- -------- -------- ----------- --------
Special Resolution
7 - To disapply
pre-emption
rights 20,003,065 98.39% 326,437 1.61% 20,329,502 85,329
----------- ------- -------- -------- ----------- --------
*Please note a vote withheld is not a vote in law and is not
counted in the calculation of votes validly cast for or against a
resolution.
Enquiries:
N4 Pharma plc
Nigel Theobald, CEO Via IFC Advisory
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP Tel: +44(0)20 3470
0470
Nominated Adviser and Joint Broker
Matthew Johnson/Kasia Brzozowska (Corporate
Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees
(Corporate Broking)
Turner Pope Investments (TPI) Limited Tel: +44(0)20 3657
0050
Joint Broker
Andy Thacker
James Pope
IFC Advisory Ltd Tel: +44(0)20 3934
6630
Financial PR
Graham Herring
Zach Cohen
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for cancer and vaccine treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for cancer and vaccine treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through preclinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGBXGDSIGGDGXX
(END) Dow Jones Newswires
April 03, 2023 09:11 ET (13:11 GMT)
N4 Pharma (AQSE:N4P.GB)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
N4 Pharma (AQSE:N4P.GB)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024